23 June 2020Big PharmaKatie Cambrook and Ben Millson
SPCs: a deep dive into CJEU case law
The European Supplementary Protection Certificate (SPC) Regulation incentivises pharmaceutical research and development by providing an extension to patent protection to compensate for time lost in obtaining a marketing authorisation (MA).
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
30 April 2020 The Court of Justice of the European Union has handed down its decision in Royalty Pharma, providing highly-anticipated guidance on supplementary protection certificates.
30 April 2020 The Court of Justice of the European Union has handed down its decision in Royalty Pharma, providing highly-anticipated guidance on supplementary protection certificates.
30 April 2020 The Court of Justice of the European Union has handed down its decision in Royalty Pharma, providing highly-anticipated guidance on supplementary protection certificates.